More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most women with breast cancer who paused endocrine ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...

Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with ...